GET DAILY SIGNALSBaird Medical (BDMD) Stock Falls -66% Over 30 Days Amid Ongoing Selling Pressure
Key Takeaways
- Baird Medical shares declined roughly 66% over the past 30 days, falling from about $0.77 to around $0.26, driven by sustained selling pressure and thin trading liquidity.
- The move extends a longer downtrend, with the stock down more than 50% over the past three months and roughly 70% over six months.
- The slide has continued despite reported revenue growth, underscoring investor concerns about the pace of commercialization and near-term cash generation.
- Regulatory approvals in markets such as Vietnam, Egypt, and Pakistan have expanded the company's footprint but have not yet translated into meaningful near-term revenue.
- A Weiss Ratings downgrade to "Sell" in early October and broader micro-cap risk contributed to negative sentiment.
- For additional detail on the stock's valuation and outlook, explore Baird Medical's Price Targets, Earnings, and Forecast pages.
- Traders tracking automated strategies may also want to explore Tickeron's Trending AI Robots.
Baird Medical (BDMD) Company Overview and Market Position
Baird Medical Investment Holdings Ltd. is a medical technology company specializing in minimally invasive ablation technologies for solid tumors. Founded in 2012 and headquartered in Guangzhou, China, the company listed on Nasdaq in October 2024 through a business combination. Its lead product, a microwave ablation (MWA) system, is FDA-cleared for soft tissue ablation and is being launched in the United States primarily for the treatment of benign thyroid nodules.
The company's technology has been adopted by a growing list of institutions, including the Mayo Clinic, Columbia University Medical Center, and The George Washington University Hospital. Beyond its core MWA platform, Baird Medical is expanding into irreversible electroporation (IRE) technology through a partnership with Alpmed and is developing an AI-powered robotic ablation system. The company reports a high gross margin of roughly 87%, reflecting a favorable geographic and revenue mix as it diversifies away from its historical concentration in Mainland China. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Baird Medical (BDMD) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, BDMD shares fell from a closing price of approximately $0.77 to around $0.26, a decline of roughly 66%. The move was punctuated by several outsized single-session declines across September and October, a pattern consistent with a thinly traded micro-cap experiencing intense selling pressure rather than a single, isolated catalyst.
The recent drop is part of a broader multi-month downtrend. Over the past three months, the stock has declined more than 50%, and it has lost roughly 70% over six months. This sustained weakness has unfolded despite a sequence of positive operational announcements, indicating that investor concerns about execution, liquidity, and cash generation have outweighed headline progress.
What Drove BDMD Stock Price in the Last 30 Days
Several verified developments shaped the stock's recent decline. In early October, Weiss Ratings downgraded its outlook on Baird Medical to a "Sell" rating, adding to negative sentiment. Around the same time, the company announced regulatory milestones, including Class C device registrations in Vietnam and preliminary approval from Egypt's drug authority, but the shares failed to respond positively as investors questioned how quickly these approvals would convert into revenue.
Broader micro-cap dynamics also weighed on the stock. With a market value in the low tens of millions of dollars and limited daily liquidity, BDMD is highly susceptible to sharp moves. The company's low cash position of roughly $0.29 million as of June 30, 2026 has reinforced concerns about its ability to fund the U.S. commercial ramp without additional capital. Combined, these factors help explain why the stock has continued to slide even as the company reports top-line growth.
What Drove BDMD Stock Performance Over the Last Quarter
The quarterly decline reflects a longer-standing narrative. Baird Medical's 2025 revenue fell 39.2% to $22.5 million as policy-driven pricing pressure and reduced procurement activity in Mainland China weighed on its core business. In response, the company accelerated an international expansion strategy, appointing veteran executive Mark Saxton to lead its U.S. subsidiary and establishing a North American production hub.
First-half 2026 results showed progress, with revenue up 24.6% to roughly $9.9 million and a swing to near breakeven from a large prior-year loss. However, much of that improvement came from aggressive cost-cutting rather than revenue acceleration, and first-half sales remained below 2024 levels. The market has treated the recovery cautiously, and the stock's multi-month slide suggests investors remain unconvinced that regulatory wins and early commercial traction can quickly scale into durable, cash-generating growth.
BDMD Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors are likely to focus on whether Baird Medical can convert its FDA-cleared U.S. presence into recurring sales. The company has said it plans to submit a 510(k) application to the FDA for its first co-developed IRE product by the end of 2026, a milestone that could shape the pipeline narrative. Additional regulatory clearances, physician adoption rates, and updates on the U.S. sales build-out will also be closely watched.
Financial risks remain front and center. The company's modest cash balance raises questions about potential future financing, while the Mainland China policy environment continues to influence the legacy business. Earnings updates, guidance, and any evidence that international revenue can scale sustainably will be key data points. These considerations are informational only and are not intended as investment advice. From what I see, this is important because near-term execution will determine whether the recent regulatory progress can stabilize the valuation.
Using Tickeron AI Tools for Deeper Analysis
In reviewing stocks like this, I frequently consult Tickeron's AI Trading Bots to evaluate automated strategies across similar micro-cap names. The platform provides a range of data-driven options that help put price action into context without replacing fundamental review. It is one of several resources I turn to when assessing momentum and risk factors in thinly traded equities.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BDMD in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 19, 2026
BDMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 23 of 31 cases where BDMD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDMD advanced for three days, in 68 of 116 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BDMD as a result. In 34 of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 47%.
The Moving Average Convergence Divergence Histogram (MACD) for BDMD turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 14 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 31%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for BDMD entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.230) is normal, around the industry mean (3.824). P/E Ratio (-0.453) is within average values for comparable stocks, (1.677). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (1.371) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. BDMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement